Cardiovascular Systems Inc (CSII) Cours

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Cytek Biosciences Set to Join S&P SmallCap 600

Cytek Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK, April 25, 2023 NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular...

Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional...

Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary...

Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a...

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

KAIZEN to assess safety and efficacy of peripheral orbital atherectomy to secure regulatory approval in Japan Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company...

Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.’s Thrombectomy System

System includes mechanical and aspiration thrombectomy devices to treat peripheral vascular disease Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and...

Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary...

Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET)  Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23...

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary...